Cart
×
Get in the Game
Accessible gaming for people with Duchenne Individuals with Duchenne are living at a time when technology is helping to make the digital world more accessible and the real world more […]
Ladies Luncheon Returns to Austin Country Club for a Palm Springs-Themed Afternoon
Annual Austin Event Raises Funds to Find a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (July 21, 2022) – CureDuchenne, a leading global nonprofit focused on funding and finding […]
NHL All-Star Ryan Getzlaf Returns to the Links for the 11th Annual Getzlaf Golf Shootout
Event Has Raised More Than $4.6 Million over the Last Decade to Find a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (July XX, 2022) – CureDuchenne, a leading global […]
Nationwide’s Success Has a Broad Impact on Duchenne Research
Kevin Flanigan, MD is a leading expert in the development of gene therapies for Duchenne, and the director of the Center for Gene Therapy in the Abigail Wexner Research Institute […]
Nomination package submitted to add Duchenne to the Recommended Uniform Screening Panel (RUSP)
Duchenne muscular dystrophy was nominated to be added to the Recommended Uniform Screening Panel (RUSP), a list of disorders that are screened for at birth. This is an important step […]
Sarepta Therapeutics Shares Clinical Data and Integrated Analysis for SRP-9001, its investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Sarepta Therapeutics Shares Clinical Data and Integrated Analysis.
Santhera Letter to the Community on NDA Filing for Vamorolone
Dear Duchenne Community, We are writing to provide some additional information to accompany our press release (attached) this week about the status of the rolling New Drug Application at the […]
Capricor Announces More Good News For CAP-1002
CureDuchenne provided early and significant funding to Capricor Therapeutics for their Duchenne program, and we are pleased to share their latest updates. One-year results from their HOPE-2 open label extension […]
Givinostat Demonstrates Positive Phase 3 Trial Results
Italfarmaco released positive topline data from their Phase 3 trial in Givinostat, an anti-fibrotic for use in ambulant boys with Duchenne over 6 years old and on a chronic steroid […]